Our @Point of Care Endocrinology Podcasts have healthcare experts discussing and providing information related to endocrinology diagnosis, treatment, management, and other important information.
Join diabetologist, Dr. Anne Peters, and nurse practitioner, Amy Peleckis, as they explore islet cell transplantation for patients with type 1 diabetes. This podcast will focus on appropriate patient selection, available and emerging islet cell therapy options and their clinical trial data, as well as best practices for managing immunosuppression posttransplantation.
Visit https://suitehome.atpointofcare.com/library/2733.01/page/0 (https://suitehome.atpointofcare.com/library/2733.01/page/0) to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
This podcast is powered by Pinecast (https://pinecast.com).
7 May 2021
S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action
Visit http://morningcommutepodcast.com/SGLT2inhibitors6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. James Januzzi and Dr. Silvio Inzucchi discuss the surge in collaboration between primary care physicians, endocrinologists, and cardiologists and the groundswell of cardiometabolic clinics. They attribute this to cardiologists moving beyond the so-called glucocentric view and focusing on how diabetes therapies might help reduce cardiovascular risk as well. Drs. Januzzi and Inzucchi will also discuss the recent guidelines that now incorporate sodium-glucose cotransporter 2 (SGLT-2) inhibitors into clinical pathways.
7 May 2021
S1E5 - SGLT-2 Inhibitors Morning Commute: The Heart Failure Connection
Visit http://morningcommutepodcast.com/SGLT2inhibitors5 (http://morningcommutepodcast.com/SGLT2inhibitors5) to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi discuss how sodium-glucose cotransporter 2 (SGLT-2) inhibitors evolved from treatments for type 2 diabetes mellitus (T2DM) to key treatments for patients with heart failure. Drs. Januzzi and Inzucchi look at the pivotal trials that thrust these treatments into the heart failure treatment limelight.
Visit http://morningcommutepodcast.com/SGLT2inhibitors4 (http://morningcommutepodcast.com/SGLT2inhibitors4) to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi will discuss SGLT-2 inhibition in cardiovascular risk reduction by taking a look at some of the pivotal clinical trial data.
Visit http://morningcommutepodcast.com/SGLT2inhibitors3 (http://morningcommutepodcast.com/SGLT2inhibitors3) to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will focus on chronic kidney disease (CKD) in patients with or without diabetes and treatment with sodium-glucose cotransporter 2 (SGLT-2) inhibitors. The bottom line is, how should these treatments be incorporated into clinical practice?
27 Feb 2021
S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients
Visit http://morningcommutepodcast.com/SGLT2inhibitors2 (http://morningcommutepodcast.com/SGLT2inhibitors2) to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss clinical trial data that look at new directions for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, particularly how they benefit patients with chronic kidney disease (CKD).
27 Feb 2021
S1E1 - SGLT-2 Inhibitors Morning Commute: A Mechanistic Explanation of Renal Benefit
Visit http://morningcommutepodcast.com/SGLT2inhibitors1 (http://morningcommutepodcast.com/SGLT2inhibitors1) to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will be discussing sodium-glucose cotransporter 2 (SGLT-2) inhibitors and their role beyond glycemic control. What are the mechanisms and renal benefit of SGLT-2 inhibitors?
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
3.0 / 5
2 ratings
Contact Endocrinology @Point of Care Podcasts
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Endocrinology @Point of Care Podcasts?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
